LETRO-2.5 Research Overview
LETRO-2.5 is a pharmaceutical-grade aromatase inhibitor manufactured by Intex Pharma, containing letrozole as the active compound. This non-steroidal research chemical belongs to the triazole class of aromatase inhibitors, specifically engineered for laboratory investigations into estrogen biosynthesis pathways. Researchers at Stroid UK Shop utilise this compound to examine the competitive inhibition of the aromatase enzyme (CYP19A1), which catalyses the conversion of androgens to estrogens in cellular models.
Laboratory Research Applications
Scientists investigate LETRO-2.5 in studies examining hormonal regulation mechanisms and estrogen-dependent cellular processes. The compound demonstrates potent aromatase inhibition properties in preclinical research models, making it valuable for examining the role of estrogen suppression in various biological pathways. Research teams studying endocrine function often incorporate this compound alongside other aromatase inhibitors to evaluate comparative efficacy profiles. Laboratory protocols frequently examine its interaction with steroid hormone pathways, particularly in conjunction with research compounds from our SARMs collection and peptide research range for comprehensive hormonal modulation studies.
Compound Specifications
| Parameter | Value |
|---|---|
| Active Compound | Letrozole |
| Concentration | 2.5mg per unit |
| CAS Number | 112809-51-5 |
| Molecular Formula | C₁₇H₁₁N₅ |
| Molecular Weight | 285.3 g/mol |
| Storage Requirements | Room temperature, dry environment |
Research Compliance
LETRO-2.5 is manufactured exclusively for in-vitro laboratory research purposes and is not intended for human consumption, therapeutic use, or any application outside controlled scientific environments. Researchers must ensure compliance with institutional guidelines and regulatory frameworks governing research chemical handling and disposal procedures.
